Oncomed Pharmaceuticals Inc. is embarking on an internal portfolio review in the wake of a phase II trial miss and a key partner loss Monday, news which pushed company shares (NASDAQ:OMED) 36.6 percent lower to close at $5.55 on Monday. Read More
Cellular Biomedicine Group Inc., of Shanghai, and GE Healthcare Life Sciences China, said they have established a strategic research collaboration to co-develop certain high-quality industrial control processes in chimeric antigen receptor T-cell (CAR-T) and stem cell manufacturing. Read More
In a sweeping enforcement action that could impact investment in small biopharma and med-tech companies for months to come, the SEC cracked down Monday on what it labeled as a fraudulent scheme in which investors were given the impression they were reading independent, unbiased analyses on investing websites when, in reality, the writers were secretly compensated for promoting the companies' stocks. Read More
Biohaven Pharmaceutical Holding Co. Ltd., a clinical-stage biopharma registered in the British Virgin Islands, filed an S-1 with the SEC for an IPO of up to $100 million. Read More
LONDON – Technology commercialization specialist Puretech Health plc has launched start-up, Nybo Therapeutics, to discover and develop monoclonal antibodies that neutralize newly discovered immunosuppressive mechanisms in pancreatic cancer. Read More
A spate of bills ranging from spurring generic competition to funding pediatric research was introduced last week just before the U.S. Congress turned the lights out for a two-week recess. Read More
Korean researchers at Daegu Gyeongbuk Institute of Science and Technology (DGIST) have discovered a new mechanism through which senescence is controlled at the cellular level and identified a means by which that mechanism's function is modulated, offering the potential to reverse the aging process. Read More
Hemostemix Inc., of Blackfalds, Alberta, said it reached an agreement with Wood Capital Ltd. on a non-brokered senior secured debt financing of C$4.4 million (US$3.29 million) in one or more tranches. The agreement also contemplates that a non-brokered or brokered private placement or placements of a minimum of C$4 million to a maximum of C$8 million will also be completed. Read More
Roche AG, of Basel, Switzerland, said its Genentech unit reported that the global, randomized phase III ALEX study met its primary endpoint and showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival) compared to the tyrosine kinase receptor inhibitor crizotinib (Xalkori, Pfizer Inc.) in people with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Read More
